@article {Speight378, author = {R Alexander Speight and John C Mansfield}, title = {Drug advances in inflammatory bowel disease}, volume = {13}, number = {4}, pages = {378--382}, year = {2013}, doi = {10.7861/clinmedicine.13-4-378}, publisher = {Royal College of Physicians}, abstract = {The pathogenesis of inflammatory bowel disease (IBD) remains incompletely understood, but is thought to be a consequence of immune dysregulation, impaired mucosal integrity, enteric bacterial dysbiosis and genetic susceptibility factors. Recent drug advances in the treatment of IBD have clarified the role of existing medication, including 5-amino-salicylic acids (5-ASAs) and has seen a burgeoning use of treatment with biologicals. With recent advances in our understanding of these debilitating diseases, it is hoped that novel therapeutic targets can be identified.}, issn = {1470-2118}, URL = {https://www.rcpjournals.org/content/13/4/378}, eprint = {https://www.rcpjournals.org/content/13/4/378.full.pdf}, journal = {Clinical Medicine} }